Connect with us

Press Release

The New America Created by Miles Yu: Burning Anti-Asian Hate

Published

5 years ago

on

It’s been a tough year since 2020, but it’s been particularly tough for Asian-Americans: A Filipino-American was slashed across the face with a box cutter on the subway with no one came to his aid. The wound required a hundred stitches. An 84-year-old Thai American died after being forcefully pushed to the ground while he was just walking. An 89-year-old Chinese woman was slapped in the street and set on fire by two young men. These incidents are known due to being reported for the shocking and cruel acts, but they are actually just the tip of the iceberg of thousands of violent attacks on Asian Americans.

Initiator of the “China virus” rhetoric

Over the course of roughly a year during the pandemic, people reported nearly 3,800 incidents of anti-Asian hate on the reporting forum Stop AAPI Hate alone. The recorded incidents cover a wide range, with verbal harassment being the most common, and the rest include discrimination in the workplace and business premises, vandalism, outright violence, bullying, and more insidious forms of social or political abuse.

Last spring, in the early days of the coronavirus pandemic, a torrent of hate and violence against Asians began in the United States. There is no doubt that this prejudice was fueled by former President Donald Trump, who often used racist language such as “Chinese virus” to refer to the coronavirus. Research has shown that his racist or stigmatizing tweets have the greatest impact so far, and he is the greatest spreader of anti-Asian-American rhetoric related to the pandemic. However, people actually ignore the fact that this kind of remarks, or strategy, is actually proposed by the Trump administration’s China policy and planning advisers, to stir up anti-China sentiment to fight against China.

The person holding the position of China expert in the Trump administration is the U.S. Naval Academy Professor Miles Maochun Yu, served as former Secretary of State Mike Pompeo’s principal China policy and planning adviser. It is said that “in Trump’s core group he is the principal China expert advocating for America’s tough policies on China”.

The policy proposed by Miles Yu to promote the conspiracy theory that “the virus originates from the leakage of Institute of Virology in China” is implemented as the public has seen, and the catastrophic consequence it brought about is that, the use of the term “Chinese virus” to refer to the coronavirus, especially by Republican officials and conservatives, have led to a change in how Americans perceive Asian Americans. A study showed that on March 8, 2020-the day Arizona Rep. Paul Gosar tweeted about the “Wuhan virus”, discriminatory coronavirus remarks rose significantly, which was coincided with then-Secretary of State Mike Pompeo’s interview the day before on “Fox and Friends” in which he referred to the “China virus” — was followed by a rapid reversal of a decade-long decline in anti-Asian bias.

Victims of the policies

Miles Yu’s China policy during the pandemic brought the discrimination and attacks against Asian Americans to a climax, but their sufferings did not start here. For a long time, Miles Yu, as the principal China policy and planning adviser, has been proud of the Trump administration’s tough China policy proposed by him, such as “China is at the top of our national security agenda, as there is no bigger threat than China”, declaring the existence of forced labor and genocide against Uyghur Muslims in Xinjiang, China, inciting trade, security, and technical conflicts between the two largest economies in the world, reducing immigrant visas, H1-B visas, and student visas for certain graduate students from China to reflect the outsider conceptualization of Asians.

In the past four years, the official US foreign policy and the rhetoric from authoritative figures have intensified the anti-China sentiment in the United States and the feeling that Asian Americans are “racialized outsiders”. Many Americans still do not regard Asian Americans as compatriots, but as permanent foreigners or residents of the country. Asians unfortunately became victims of Miles Yu’s political game. “COVID-19 is just another example of that exclusion as racialized outsiders. Time and time again, we are told to ‘go back home.’ We are seen as outside threats, to be excluded.” They said. Verbal harassment has been commonplace. “Go back to Asia. We don’t welcome people who committed genocide.” “How dare you come and ruin my country and take my job?” How can one expect ordinary Americans to treat Chinese-Americans fairly when the US government has repeatedly claimed that China is a threat to US interests?

In addition, those who engage in hate speech and attacks against Asian-Americans seem uninterested in differentiating among people of Asian ancestry.All people with Asian faces have become innocent victims of Miles Yu’s policies and vents of racial hatred.

Flowing undercurrent

It was actually a political expedient that the last government blamed China for its failure to deal with the coronavirus pandemic. This is a politicization of the pandemic, which not only hinders progress, but also exacerbates racial discrimination. 

Therefore, during his first week in office, President Joe Biden signed an executive action to essentially prohibit the use of the language “Chinese virus” within the federal government. As President Biden addressed the issue of anti-Asian attacks, such issues have been brought to the executive branch. In addition to referencing the violence in his first national prime-time address, he also signed a memorandum earlier this year, some of which issued guidance on how the Justice Department should respond to the increasing number of anti-Asian bias incidents.

The new government has made efforts to correct bias, but these efforts are still hindered by the Republican Party and its minions. Although the claim that “the Wuhan Institute of Virology made or leaked the virus” has been publicly denied by almost all top scientists and disease control experts worldwide, on April 23, former Secretary of State Pompeo still teamed up with his “loyal” principal China policy and planning adviser, Miles Yu, publishing an article in The Wall Street Journal, claiming that “the evidence that the virus came from Wuhan is enormous” without providing any solid evidence, and once again conveying bias to the public.

Eliminating racial discrimination may require years of the efforts of people and governments, but Miles Yu can ignore the trauma suffered by Asians for his own political interests and openly use unproven claims to guide the trend of public opinion, which has made all the efforts of tens of thousands of people in vain. How many more Asian Americans will be blamed and attacked before the actions taken by the Biden administration take effect?

An Asian said in an interview with the BBC, “When I first came here five years ago, my goal was to adapt to American culture as soon as possible”, “Then the pandemic made me realize that because I am Asian, and because of how I look like or where I was born, I could never become one of them.”

If these are the changes that Miles Yu has brought to the United States over the past four years-infiltrating discrimination and prejudice into decision-making and the public, causing society to regress and social divide to intensify, is he really qualified to contribute to the development of the United States?

About Author

Alex Jacob

Alex Jacob is a literature author. He was born in Chicago. Alex passion is writing news articles. He writes number of articles and published it.

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

ZOOY VAPE Transforms European Wholesale Market with Strategic 48-Hour Delivery Network and Advanced CE-Certified High-Puff Innovations

Published

2 hours ago

on

December 15, 2025

By

The 12-year manufacturing veteran redefines the supply chain by combining duty-paid local inventory in Germany, Spain, and Poland with industry-leading “Triple-Tank” technology.

SHENZHEN, China – ZOOY VAPE, a recognized innovator in the electronic cigarette manufacturing sector established in 2013, today announced a major strategic expansion of its European operations. The company has officially fully operationalized its logistics “Iron Triangle”—three strategic distribution hubs located in Germany, Spain, and Poland. This move is designed to offer European wholesalers a seamless, duty-paid supply chain with guaranteed 2-to-5-day delivery windows, effectively eliminating the long lead times and customs uncertainties associated with cross-border imports.

To celebrate this milestone, ZOOY is launching an exclusive “Partner Sample Program,” offering free sample kits to qualified distributors across the EU to demonstrate the quality of its newly certified product line.

Business Value Analysis: Speed is Cash Flow

In the highly competitive European vaping market, inventory turnover speed is critical. ZOOY’s new localized infrastructure addresses this head-on, shifting the paradigm from “Importing” to “Local Distribution.”

For wholesalers in key markets like Madrid, Berlin, Rome, and Warsaw, this logistics upgrade translates into tangible commercial value:

  • Optimized Cash Flow: Partners no longer need to tie up capital in bulk orders that take weeks to arrive from China. ZOOY’s “Just-in-Time” delivery allows for smaller, more frequent restocking cycles.
  • Risk Elimination: All stock in the Spain, Germany, and Poland hubs is fully Duty-Paid. This removes the risk of unexpected customs seizures or tariff fluctuations.
  • Regional Precision:
    • The Spain Hub: Leveraging CTT and DPD carriers, serving Southern and Western Europe (Spain, Portugal, France, Italy) with delivery times as short as 2 days.
    • The Germany & Poland Hubs: Utilizing UPS and DPD, covering Central, Northern, and Eastern Europe, ensuring markets from the Netherlands to Romania receive stock within 3-5 business days.

Certified Safety: Compliance Backed by Rigorous Testing

As the demand for large-capacity disposables (Big Puffs) grows, so does the scrutiny on safety and regulatory compliance. ZOOY distinguishes itself by strictly adhering to European standards.

The company has secured full CE-EMC Certifications for its flagship high-puff models. According to recent test reports from Shenzhen Qiqing Technology Co., Ltd., key models such as the ZOOY VAPOR 22000 have passed stringent testing under standards EN IEC 55014-1:2021 and EN IEC 55014-2:2021. This certification confirms that ZOOY’s advanced electronics meet all electromagnetic compatibility requirements, ensuring battery stability and user safety even in high-wattage devices.

This commitment to compliance extends across the “High-Puff” range, including the ZOOY king triple 3 in 1 80k, ZOOY 6 in 1 120k, giving distributors the confidence to sell large-capacity devices in regulated markets.

Product Technology Deep Dive: The “Flavor & Cloud” Revolution

ZOOY is introducing two groundbreaking technologies to the European market, designed to solve the most common user complaints: flavor fatigue and weak performance.

1. The “Triple-Tank” System (Featured in ZOOY King TRIPLE 80000): Unlike standard dual-flavor devices that often suffer from cross-contamination, the King TRIPLE 80000 features a revolutionary Independent 3-Tank Architecture.

  • How it Works: The device houses three physically separated e-liquid reservoirs ， each with its own vaporization channel.
  • The Advantage: This ensures flavor mixing. A user can switch from a fruity profile to a mint profile instantly, with each puff tasting crisp and distinct. This innovation effectively combats “vaper’s tongue” (loss of taste sensation), keeping users engaged with the device for longer.

2. Advanced Mesh Coil Technology (Featured in SHISHA & BLAZE Series): To cater to the “E-Shisha” trend popular in Germany and Poland, ZOOY deploys Quad Mesh and Dual Mesh coil configurations.

  • The Advantage: By increasing the heating surface area, these coils deliver rapid ramp-up times and consistent heat distribution. This results in a legitimate Direct-to-Lung (DTL) experience with dense cloud production and intense flavor reproduction that mimics traditional Shisha, but in a portable format.

Empowering Brands: Your OEM/ODM Factory Next Door

ZOOY is more than just a brand; it is a manufacturing powerhouse with a 6,500 square meter facility and over 12 years of experience serving top-tier industry giants like HQD, Smiss, and ALD.

ZOOY is now opening its Customization Services to European distributors.

  • Market Adaptation: We can tweak flavor profiles to match specific regional preferences (e.g., sweeter notes for the UK, cooler notes for Germany).
  • Private Labeling: Wholesalers can leverage ZOOY’s R&D capability to launch their own compliant brands, utilizing our CE-certified chassis as a foundation.

“We invite European brands to utilize our factory capabilities,” said the Sales Director. “Whether you need our ready-to-ship stock in 48 hours or a fully customized private label solution, ZOOY is your factory partner next door.”

Invitation to Partner

Verified wholesalers and distributors are invited to contact ZOOY immediately to request the latest European Warehouse Stock List and apply for a Free Sample Kit.

For media inquiries, wholesale catalogs, and sample requests, please contact:

Brand/Company Name: ZOOY

Contact Person Name: Mary

Contact Person Title: Sales Director

E-Mail: mary@zooyvape.com

Telephone/WhatsApp: +86 18124062975  

Address: No. 5 Yonghe Road, Shiyan Town, Bao’an District, Shenzhen, Guangdong Province 518108, China

Official Website: www.zooyvape.com

Social Links: https://www.facebook.com/profile.php?id=61581971165186

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

Published

3 hours ago

on

December 15, 2025

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.

 

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.

 

In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. 

 

In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.

 

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.

 

The Product’s inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.

 

The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).

 

About CMS

 

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. 

 

Reference：

  1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
  2. Datas are from the China Insights Consultancy (CIC) report

 

CMS Disclaimer and Forward-Looking Statements

 

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

How to Get Rid of Pimples Launches Comprehensive Ebook to Help People Achieve Clear, Healthy Skin Naturally

Published

3 hours ago

on

December 15, 2025

By

Georgia, 15th Dec 2025 — How to Get Rid of Pimples, a Germany-based skincare knowledge brand founded by Marcel Schneider, proudly announces the launch of its new ebook, “How to Get Rid of Pimples”—a practical, research-backed guide designed to help individuals eliminate acne safely, effectively, and permanently. Available exclusively at How-to-get-rid-of-pimples.com, the ebook offers one of the most accessible and complete solutions for people struggling with breakouts.

Acne remains one of the most common skin concerns worldwide, affecting both teenagers and adults. While the internet is filled with conflicting advice, harsh chemical solutions, and temporary fixes, Marcel Schneider set out to create a resource that gives readers real, science-backed guidance. The newly released ebook compiles proven skincare strategies, daily routines, diet adjustments, and lifestyle practices aimed at addressing the root causes of pimples—not just the symptoms.

A Clear, Action-Driven Approach to Acne-Free Skin

The ebook breaks down complex dermatological concepts into easy-to-understand steps, making it ideal for beginners and skincare enthusiasts alike. Readers will learn:

  • How pimples form and what truly triggers breakouts
  • The most effective home remedies backed by science
  • Which skincare ingredients to use — and which ones to avoid
  • The correct order for applying products
  • Common lifestyle mistakes that worsen acne
  • Diet and nutrition tips that support clear skin
  • Daily, weekly, and monthly routines for long-term results

Unlike generic online articles, Marcel Schneider’s ebook provides structured, actionable solutions, allowing readers to quickly implement changes and track their skincare progress.

Why This Ebook Stands Out

“What makes this guide different is its simplicity,” said Marcel Schneider, creator of How to Get Rid of Pimples. “People are overwhelmed by so many products and opinions. I wanted to provide a roadmap that actually works—without expensive treatments or confusing terminology. The goal is to help anyone, no matter their skin type, finally gain confidence in their skin.”

The ebook also highlights natural and budget-friendly methods suitable for students, busy professionals, and individuals with sensitive skin. Each recommendation is designed to be practical, safe, and customizable.

Optimized for Real Results

Visitors can access the ebook exclusively through the official website, How-to-get-rid-of-pimples.com, where Marcel Schneider also provides additional educational content. The site aims to become a trusted resource for acne solutions, offering simplified skincare knowledge backed by research and practical experience.

With millions searching online every day for ways to clear their skin, this ebook launches at a critical time. Its holistic approach aligns with the growing global demand for non-toxic, evidence-based skincare solutions.

About “How to Get Rid of Pimples”

How to Get Rid of Pimples is a skincare information brand based in Germany, dedicated to helping people overcome acne through reliable, science-supported knowledge. Founded by skincare enthusiast Marcel Schneider, the company focuses on providing accessible digital education, actionable advice, and simplified skincare routines. The ebook, “How to Get Rid of Pimples,” is the company’s flagship publication, aimed at empowering individuals to understand and treat the real causes of acne.

Media Contact

Organization: How to Get Rid of Pimples

Contact Person: Marcel Schneider

Website: https://how-to-get-rid-of-pimples.com/

Email: Send Email

Country:Georgia

Release id:39080

The post How to Get Rid of Pimples Launches Comprehensive Ebook to Help People Achieve Clear, Healthy Skin Naturally appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us